KAT2B and metastatic colorectal cancer: If KAT2B could be used as an independent biomarker for olaparib treatment, it would ideally complement our previous findings on the persistence of BRCA-ness mutational signatures in metastatic colorectal cancers [5,6] to better predict the putative response to olaparib in metastatic colorectal cancer patients.